| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
DGAT1-IN-3, also known as RO-5006036, is a novel,potent, selective and orally bioavailable inhibitor of DGAT-1, with IC50s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. DGAT1-IN-3 could be used to research of obesity, dyslipidemia, and metabolic syndrome.orally bioavailable DGAT-1 inhibitor with IC50 values of 120 nM for rat DGAT-1 and 38 nM for human DGAT-1. Research on obesity, dyslipidemia, and the metabolic syndrome may benefit from the use of DGAT1-IN-3.
| Targets |
Glutaminase C (IC50 = 38 nM); rat DGAT-1 (IC50 = 120 nM)
|
|---|---|
| ln Vitro |
DGAT1-IN-3 uses an IC20 of 0.2 μM to block the potassium channel encoded by the human ether-a-go-go-related gene (hERG)[1].
DGAT1-IN-3 inhibits inhibits human DGAT-1 with an EC50 of 0.66 μM in CHOK1 cells[1]. |
| ln Vivo |
DGAT1-IN-3 (5-50 mg/kg; p.o once daily for three weeks) enhances lipid profile and lowers weight gain and plasma triglycerides[2].
DGAT1-IN-3 (50 mg/kg; p.o) has a maximum exposure level in plasma (Cmax) of 24 μM and a good oral bioavailability of 77%[2]. DGAT1-IN-3 (5 mg/kg; i.v) has low clearance (13.5 mL/min/kg) and terminal elimination half-lives (1.95 h)[2]. |
| Animal Protocol |
Three-month-old male Sprague Dawley DIO rats (fed with a high-fat diet)[2]
0, 5, 25, 50 mg/kg; once daily for three weeks P.o. administration |
| References |
| Molecular Formula |
C20H19F3N4O3
|
|---|---|
| Molecular Weight |
420.385074853897
|
| Exact Mass |
420.1409
|
| Elemental Analysis |
C, 57.14; H, 4.56; F, 13.56; N, 13.33; O, 11.42
|
| CAS # |
939375-07-2
|
| Related CAS # |
939375-07-2
|
| Appearance |
Solid powder
|
| SMILES |
CN(CCOC)C1=NC=C(C=C1)NC(=O)C2=C(OC(=N2)C3=CC=CC=C3)C(F)(F)F
|
| InChi Key |
QEZWDFXCTTZZRI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19F3N4O3/c1-27(10-11-29-2)15-9-8-14(12-24-15)25-18(28)16-17(20(21,22)23)30-19(26-16)13-6-4-3-5-7-13/h3-9,12H,10-11H2,1-2H3,(H,25,28)
|
| Chemical Name |
N-[6-[2-methoxyethyl(methyl)amino]pyridin-3-yl]-2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carboxamide
|
| Synonyms |
DGAT1-IN-3; RO-5006036; RO5006036; RO 5006036
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~237.9 mM)
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3787 mL | 11.8937 mL | 23.7874 mL | |
| 5 mM | 0.4757 mL | 2.3787 mL | 4.7575 mL | |
| 10 mM | 0.2379 mL | 1.1894 mL | 2.3787 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA